These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38696310)

  • 21. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.
    Ruopp NF; Cockrill BA
    JAMA; 2022 Apr; 327(14):1379-1391. PubMed ID: 35412560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety.
    Murdaca G; Spanò F; Puppo F
    Expert Opin Drug Saf; 2014 Mar; 13(3):295-305. PubMed ID: 24387049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effectiveness of pulmonary arterial hypertension drugs in treatment-naive patients: a network meta-analysis.
    Petrovič M; Locatelli I
    J Comp Eff Res; 2020 Jan; 9(1):7-22. PubMed ID: 31845591
    [No Abstract]   [Full Text] [Related]  

  • 25. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?
    Seferian A; Simonneau G
    Eur Respir Rev; 2013 Sep; 22(129):217-26. PubMed ID: 23997048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension.
    Koo R; Lo J; Bock MJ
    Cardiol Young; 2019 Jun; 29(6):849-851. PubMed ID: 31379316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid Titration of Intravenous Treprostinil to Treat Severe Pulmonary Arterial Hypertension Postpartum: A Retrospective Observational Case Series Study.
    Wang T; Lu J; Li Q; Chen Y; Ye Q; Gao J; Yang D; Zhao L; Huang J; Zhang J
    Anesth Analg; 2019 Dec; 129(6):1607-1612. PubMed ID: 31743181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treprostinil for pulmonary hypertension.
    Vachiéry JL; Naeije R
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tadalafil (Adcirca) for pulmonary arterial hypertension.
    Med Lett Drugs Ther; 2009 Nov; 51(1324):87-8. PubMed ID: 19890245
    [No Abstract]   [Full Text] [Related]  

  • 30. Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
    Humbert M; McLaughlin V; Gibbs JSR; Gomberg-Maitland M; Hoeper MM; Preston IR; Souza R; Waxman A; Escribano Subias P; Feldman J; Meyer G; Montani D; Olsson KM; Manimaran S; Barnes J; Linde PG; de Oliveira Pena J; Badesch DB;
    N Engl J Med; 2021 Apr; 384(13):1204-1215. PubMed ID: 33789009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-Center Experience Using Selexipag in a Pediatric Population.
    Gallotti R; Drogalis-Kim DE; Satou G; Alejos J
    Pediatr Cardiol; 2017 Oct; 38(7):1405-1409. PubMed ID: 28702718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Macitentan (Opsumit) for pulmonary arterial hypertension.
    Med Lett Drugs Ther; 2014 Feb; 56(1436):15-6. PubMed ID: 24663031
    [No Abstract]   [Full Text] [Related]  

  • 33. Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil, and Oral Selexipag in a Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension.
    Corboz MR; Plaunt AJ; Malinin VS; Li Z; Gauani H; Chun D; Cipolla D; Perkins WR; Chapman RW
    J Pharmacol Exp Ther; 2022 Oct; 383(1):103-116. PubMed ID: 36507843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bosentan.
    Chin K; Channick R
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):175-82. PubMed ID: 15151466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
    Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
    Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
    J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ambrisentan: a review of its use in pulmonary arterial hypertension.
    Rivera-Lebron BN; Risbano MG
    Ther Adv Respir Dis; 2017 Jun; 11(6):233-244. PubMed ID: 28425346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
    Radosevich JJ; DeChristopher A; Irandost M; Fann J; Feldman J
    Am J Health Syst Pharm; 2020 Jul; 77(15):1208-1212. PubMed ID: 32620953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selexipag (Uptravi) for pulmonary arterial hypertension.
    Med Lett Drugs Ther; 2016 Feb; 58(1488):21-3. PubMed ID: 26859660
    [No Abstract]   [Full Text] [Related]  

  • 40. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
    J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.